对卡博普拉丁过敏反应的危险因素:系统性审查和元分析
Ha Young Jang1, Boyoon Choi2, In-Wha Kim3
1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, South Korea; College of Pharmacy, Gachon University, Incheon, South Korea.
对卡博普拉丁的过敏反应很常见. 关键的风险因素包括过敏,BRCA突变,更长的治疗休息,更高的剂量,复发和年轻的年龄,有助于个性化风险评估.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 对卡博普拉丁的过敏反应 (HSR) 复杂化了癌症治疗和生存.
- 之前对卡博普拉丁HSR风险因素的研究得出了不确定的结果.
研究的目的:
- 系统地审查和进行元分析,以确定癌症患者对碳烯素HSR的共识风险因素.
- 为这些风险因素提供全面的定量评估.
主要方法:
- 按照PRISMA指南进行系统审查和元分析.
- 搜索了MEDLINE,Embase和韩国医学数据库进行病例控制或队列研究.
- 包括19项使用纽卡斯尔-太华尺度进行质量评估后的研究.
主要成果:
- 卡博普拉丁HSRs的确定的风险因素:过敏史 (OR=1.76),BRCA突变 (OR=4.03),没有卡博普拉丁的间隔≥12个月 (OR=4.93).
- 其他因素包括累积剂量增加 (SMD=0.58),复发 (OR=2.26),年龄较小 (SMD=-0.15).
结论:
- 这一元分析提供了对卡博普拉丁HSR风险因素的全面评估.
- 结果可以为个性化风险评估和预防策略提供信息,以改善患者安全和结果.
更多相关视频
07:54Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
相关概念视频
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Mutagenicity and Carcinogenicity
Allergic Drug Reactions
